Vertex Pharmaceuticals annual total debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Total Debt Growth & History (VRTX)
Vertex Pharmaceuticals's total debt was $2.04B for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.04B | $286.5M | +16.38% |
| 2024 | 2024-12-31 | $1.75B | $941.1M | +116.42% |
| 2023 | 2023-12-31 | $808.4M | −$91.3M | −10.15% |
| 2022 | 2022-12-31 | $899.7M | −$67.7M | −7.00% |
| 2021 | 2021-12-31 | $967.4M | $24.9M | +2.64% |
| 2020 | 2020-12-31 | $942.5M | $269.3M | +40.01% |
| 2019 | 2019-12-31 | $673.2M | $76.5M | +12.83% |
| 2018 | 2018-12-31 | $596.6M | $553.6M | +1286.66% |
| 2017 | 2017-12-31 | $43.0M | −$11.4M | −20.91% |
| 2016 | 2016-12-31 | $54.4M | −$4.1M | −6.95% |
| 2015 | 2015-12-31 | $58.5M | $1.4M | +2.40% |
| 2014 | 2014-12-31 | $57.1M | −$8.5M | −13.02% |
| 2013 | 2013-12-31 | $65.6M | $36.8M | +127.33% |
| 2012 | 2012-12-31 | $28.9M | $28.9M | — |
| 2011 | 2011-12-31 | $0 | — | — |
Vertex Pharmaceuticals quarterly total debt
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.98B | $450.2M | +29.47% |
| Q1 2026 | 2026-03-31 | $1.99B | $337.4M | +20.46% |
| Q4 2025 | 2025-12-31 | $2.04B | $286.5M | +16.38% |
| Q3 2025 | 2025-09-30 | $1.83B | $60.7M | +3.42% |
| Q2 2025 | 2025-06-30 | $1.53B | $594.0M | +63.64% |
| Q1 2025 | 2025-03-31 | $1.65B | $927.8M | +128.63% |
| Q4 2024 | 2024-12-31 | $1.75B | $941.1M | +116.42% |
| Q3 2024 | 2024-09-30 | $1.77B | $1.03B | +138.23% |
| Q2 2024 | 2024-06-30 | $933.4M | $165.8M | +21.60% |
| Q1 2024 | 2024-03-31 | $721.3M | −$67.9M | −8.60% |
| Q4 2023 | 2023-12-31 | $808.4M | −$91.3M | −10.15% |
| Q3 2023 | 2023-09-30 | $744.7M | −$79.9M | −9.69% |
| Q2 2023 | 2023-06-30 | $767.6M | −$79.7M | −9.41% |
| Q1 2023 | 2023-03-31 | $789.2M | −$83.3M | −9.55% |
| Q4 2022 | 2022-12-31 | $899.7M | −$67.7M | −7.00% |
| Q3 2022 | 2022-09-30 | $824.6M | −$52.2M | −5.95% |
| Q2 2022 | 2022-06-30 | $847.3M | −$46.5M | −5.21% |
| Q1 2022 | 2022-03-31 | $872.5M | −$26.3M | −2.93% |
| Q4 2021 | 2021-12-31 | $967.4M | $24.9M | +2.64% |
| Q3 2021 | 2021-09-30 | $876.8M | $61.8M | +7.58% |
| Q2 2021 | 2021-06-30 | $893.8M | $371.8M | +71.21% |
| Q1 2021 | 2021-03-31 | $898.8M | $365.8M | +68.65% |
| Q4 2020 | 2020-12-31 | $942.5M | $269.3M | +40.01% |
| Q3 2020 | 2020-09-30 | $815.0M | $165.2M | +25.43% |
| Q2 2020 | 2020-06-30 | $522.1M | −$134.9M | −20.53% |
| Q1 2020 | 2020-03-31 | $533.0M | −$134.2M | −20.11% |
| Q4 2019 | 2019-12-31 | $673.2M | $76.5M | +12.83% |
| Q3 2019 | 2019-09-30 | $649.8M | $623.1M | +2338.09% |
| Q2 2019 | 2019-06-30 | $657.0M | $626.9M | +2083.29% |
| Q1 2019 | 2019-03-31 | $667.1M | $633.3M | +1871.95% |
| Q4 2018 | 2018-12-31 | $596.6M | $553.6M | +1286.66% |
| Q3 2018 | 2018-09-30 | $26.7M | −$13.5M | −33.60% |
| Q2 2018 | 2018-06-30 | $30.1M | −$13.4M | −30.87% |
| Q1 2018 | 2018-03-31 | $33.8M | −$15.8M | −31.83% |
| Q4 2017 | 2017-12-31 | $43.0M | −$11.4M | −20.91% |
| Q3 2017 | 2017-09-30 | $40.1M | −$9.4M | −18.89% |
| Q2 2017 | 2017-06-30 | $43.5M | −$8.2M | −15.91% |
| Q1 2017 | 2017-03-31 | $49.6M | −$6.6M | −11.66% |
| Q4 2016 | 2016-12-31 | $54.4M | −$4.1M | −6.95% |
| Q3 2016 | 2016-09-30 | $49.5M | −$3.9M | −7.37% |
| Q2 2016 | 2016-06-30 | $51.8M | −$5.1M | −8.90% |
| Q1 2016 | 2016-03-31 | $56.2M | −$10.0M | −15.07% |
| Q4 2015 | 2015-12-31 | $58.5M | $1.4M | +2.40% |
| Q3 2015 | 2015-09-30 | $53.4M | −$6.9M | −11.43% |
| Q2 2015 | 2015-06-30 | $56.8M | −$7.9M | −12.26% |
| Q1 2015 | 2015-03-31 | $66.1M | −$1.7M | −2.47% |
| Q4 2014 | 2014-12-31 | $57.1M | −$8.5M | −13.02% |
| Q3 2014 | 2014-09-30 | $60.3M | $6.5M | +12.11% |
| Q2 2014 | 2014-06-30 | $64.8M | $26.0M | +67.11% |
| Q1 2014 | 2014-03-31 | $67.8M | $44.8M | +194.13% |
| Q4 2013 | 2013-12-31 | $65.6M | $36.8M | +127.33% |
| Q3 2013 | 2013-09-30 | $53.8M | $53.8M | — |
| Q2 2013 | 2013-06-30 | $38.8M | $38.8M | — |
| Q1 2013 | 2013-03-31 | $23.1M | $23.1M | — |
| Q4 2012 | 2012-12-31 | $28.9M | $28.9M | — |
| Q3 2012 | 2012-09-30 | $0 | −$105.0M | — |
| Q2 2012 | 2012-06-30 | $0 | −$105.0M | — |
| Q1 2012 | 2012-03-31 | $0 | −$105.0M | — |
| Q4 2011 | 2011-12-31 | $0 | — | — |
| Q3 2011 | 2011-09-30 | $105.0M | — | — |
| Q2 2011 | 2011-06-30 | $105.0M | — | — |
| Q1 2011 | 2011-03-31 | $105.0M | — | — |
Vertex Pharmaceuticals total debt trends
Over the last five fiscal years, Vertex Pharmaceuticals's total debt increased from $942.5M to $2.04B, a change of $1.09B. The latest reported quarter, Q2 2026, shows $1.98B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗Community posts
Vertex adds detailed kidney-response data and launches patient-experience trial
Vertex ($VRTX) released additional Phase 3 RAINIER findings for povetacicept in IgA nephropathy. At week 36, 42.2% of treated participants achieved a urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% receiving p ...
